B Lauterbach1, V Kakkassery2, D Debus3, L M Heindl4,5, E S Schultz3. 1. Klinik für Dermatologie, Klinikum Nürnberg, Paracelsus Medizinische Privatuniversität, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland. bianca.lauterbach@klinikum-nuernberg.de. 2. Klinik und Poliklinik für Augenheilkunde, Universitätsmedizin Rostock, Rostock, Deutschland. 3. Klinik für Dermatologie, Klinikum Nürnberg, Paracelsus Medizinische Privatuniversität, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland. 4. Zentrum für Augenheilkunde, Universitätsklinikum zu Köln, Köln, Deutschland. 5. Centrum für Integrierte Onkologie (CIO), Köln-Bonn, Deutschland.
Abstract
BACKGROUND: Basal cell carcinomas are the most common periocular malignant tumor. In advanced periocular basal cell carcinoma, vismodegib is a new treatment option which might potentially avoid surgical eye removal. CASE REPORT: We treated a 76-year-old patient unwilling to consent to surgery with vismodegib for advanced periocular basal cell carcinoma on the left forehead that had already undergone several previous treatments. After initial partial remission, the tumor regrew under ongoing therapy, so that radical surgical excision including orbital exenteration was performed. Unfortunately, the patient died thereafter due to septic multi-organ failure. CONCLUSION: Basal cell carcinoma and its new treatment options are gaining importance for ophthalmology due to rising incidence and prevalence rates. Vismodegib is a new encouraging option. However, for advanced tumors, it must be resolved whether complete histological remission may be achieved to avoid surgical intervention, or whether the area of resection can be significantly reduced. Current multicenter studies investigate these aspects further (ClinicalTrails.gov identifier: NCT03035188).
BACKGROUND:Basal cell carcinomas are the most common periocular malignant tumor. In advanced periocular basal cell carcinoma, vismodegib is a new treatment option which might potentially avoid surgical eye removal. CASE REPORT: We treated a 76-year-old patient unwilling to consent to surgery with vismodegib for advanced periocular basal cell carcinoma on the left forehead that had already undergone several previous treatments. After initial partial remission, the tumor regrew under ongoing therapy, so that radical surgical excision including orbital exenteration was performed. Unfortunately, the patient died thereafter due to septic multi-organ failure. CONCLUSION:Basal cell carcinoma and its new treatment options are gaining importance for ophthalmology due to rising incidence and prevalence rates. Vismodegib is a new encouraging option. However, for advanced tumors, it must be resolved whether complete histological remission may be achieved to avoid surgical intervention, or whether the area of resection can be significantly reduced. Current multicenter studies investigate these aspects further (ClinicalTrails.gov identifier: NCT03035188).
Authors: Shalini V Mohan; Julia Chang; Shufeng Li; A Solomon Henry; Douglas J Wood; Anne Lynn S Chang Journal: JAMA Dermatol Date: 2016-05-01 Impact factor: 10.282
Authors: Mina Sarah Ally; Sumaira Aasi; Ashley Wysong; Claudia Teng; Eric Anderson; Irene Bailey-Healy; Anthony Oro; Jinah Kim; Anne Lynn Chang; Jean Yuh Tang Journal: J Am Acad Dermatol Date: 2014-06-11 Impact factor: 11.527
Authors: Nicole Basset-Seguin; Axel Hauschild; Jean-Jacques Grob; Rainer Kunstfeld; Brigitte Dréno; Laurent Mortier; Paolo A Ascierto; Lisa Licitra; Caroline Dutriaux; Luc Thomas; Thomas Jouary; Nicolas Meyer; Bernard Guillot; Reinhard Dummer; Kate Fife; D Scott Ernst; Sarah Williams; Alberto Fittipaldo; Ioannis Xynos; Johan Hansson Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: Aleksandar Sekulic; Michael R Migden; Anthony E Oro; Luc Dirix; Karl D Lewis; John D Hainsworth; James A Solomon; Simon Yoo; Sarah T Arron; Philip A Friedlander; Ellen Marmur; Charles M Rudin; Anne Lynn S Chang; Jennifer A Low; Howard M Mackey; Robert L Yauch; Richard A Graham; Josina C Reddy; Axel Hauschild Journal: N Engl J Med Date: 2012-06-07 Impact factor: 91.245
Authors: M Sand; F G Bechara; T Gambichler; D Sand; M R Friedländer; M Bromba; R Schnabel; S Hessam Journal: Ann Oncol Date: 2015-11-16 Impact factor: 32.976
Authors: Alexander C Rokohl; Heike Löser; Joel M Mor; Niklas Loreck; Konrad R Koch; Ludwig M Heindl Journal: Ophthalmologe Date: 2020-01 Impact factor: 1.059
Authors: Vinodh Kakkassery; Steffen Emmert; Irenäus A Adamietz; György Kovács; Anselm M Jünemann; Caroline Otte; Michael Zimbelmann; Anton Brosig; Salvatore Grisanti; Ludwig M Heindl Journal: Ophthalmologe Date: 2020-02 Impact factor: 1.059